
Tebentafusp demonstrated superior overall survival (OS) compared to pembrolizumab in a Phase 3 trial for untreated metastatic uveal melanoma (mUM). In a propensity score analysis, tebentafusp was compared to nivolumab plus ipilimumab (N+I) from a different trial. Adjusted OS favored tebentafusp, with a hazard ratio (HR) of 0.52 and a 1-year OS rate of 73% versus 50% for N+I. Sensitivity analyses confirmed the consistent superiority of tebentafusp. These findings further support tebentafusp as the standard of care for untreated mUM patients.
Like
Save
Share